MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
HOUSTON and DUBLIN ― The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic ...